1. Atkins, M. B., Kunkel, L., Sznol, M. & Rosenberg, S. A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6 Suppl 1, S11-14 (2000). 2. Waldmann, T. A. Cytokines in Cancer Immunotherapy. Cold Spring Harb Perspect Biol 10, doi:10.1101/cshperspect.a028472 (2018).3. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529-533, doi:10.1038/nature10975 (2012).4. Mumm, J. B. et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20, 781-796, doi:10.1016/j.ccr.2011.11.003 (2011).5. Tang, H. et al. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell 29, 285-296, doi:10.1016/j.ccell.2016.02.004 (2016).6. Okamura, H. et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378, 88-91, doi:10.1038/378088a0 (1995).7. Nakanishi, K., Yoshimoto, T., Tsutsui, H. & Okamura, H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19, 423474,doi:10.1146/annurev.immunol.19.1.423 (2001).8. Tarhini, A. A. et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115, 859-868, doi:10.1002/cncr.24100 (2009).9. Robertson, M. J. et al. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 14, 3462-3469, doi:10.1158/1078-0432.CCR-07-4740 (2008).10. Novick, D. et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10, 127-136 (1999).11. Aizawa, Y. et al. Cloning and expression of interleukin-18 binding protein. FEBS Lett 445, 338-342, doi:10.1016/s0014-5793(99)00148-9 (1999).12. Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20, 326-336, doi:10.1038/s41590-019-0312-6 (2019).